Asset Planning Corporation’s AbbVie ABBV Stock Holding History

Asset Planning Corporation’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-829	Closed	-$89K	–	30
2020 Q4	$89K	Buy	+829	New	+$79.7K	0.09%	45

Other funds holding ABBV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Berkshire Hathaway Omaha, Nebraska $263B AUM 16.68% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Asset Planning Corporation's ABBV Position: Q1 2021 in Review

Asset Planning Corporation sold out of AbbVie (ABBV) in Q1 2021, closing a stake of 829 shares — an estimated $89K sold.

Asset Planning Corporation first reported a position in ABBV in Q4 2020 and held it in 1 quarter. The position peaked at $89K in Q4 2020. 2,615 funds tracked by Wall St. Rank hold ABBV as of Q1 2021.

Asset Planning Corporation reported no remaining AbbVie position as of Q1 2021 after selling out during the quarter.
Asset Planning Corporation sold 829 AbbVie shares in Q1 2021, an estimated $89K.
Asset Planning Corporation first reported a position in AbbVie in Q4 2020 and held it in 1 quarter.
Asset Planning Corporation's AbbVie position peaked at $89K in Q4 2020.
2,615 funds tracked by Wall St. Rank held AbbVie as of Q1 2021.

Based on Asset Planning Corporation's 13F filing for Q1 2021, filed 17 May 2021.